Reynald Castañeda

No­var­tis is buy­ing gene ther­a­py and neu­ro­science biotech Kate Ther­a­peu­tics in a deal worth $1.1 bil­lion in up­front and mile­stone pay­ments, the Swiss phar­ma con­firmed

As­traZeneca has con­clud­ed its price ne­go­ti­a­tions with the IRA for its block­buster drug Farx­i­ga, in the lat­est up­date for phar­ma com­pa­nies un­der­go­ing the process. …

Wel­come to End­points News’ man­u­fac­tur­ing briefs, where we bring you es­sen­tial news on new builds, col­lab­o­ra­tions, re­calls and more. John­son & John­son will Sign up

In an ef­fort to “evolve” its glob­al de­vel­op­ment or­ga­ni­za­tion, No­var­tis is set to ex­it a tech­ni­cal re­search and de­vel­op­ment site in San Diego, the Swiss

Bio­mea Fu­sion’s Phase 1/2 co­va­lent menin in­hibitor pro­gram in di­a­betes has been placed on full clin­i­cal hold due to “pos­si­ble” drug-re­lat­ed he­pa­to­tox­i­c­i­ty. Liv­er en­zyme el­e­va­tions

Take­da’s mul­ti­year “ef­fi­cien­cy pro­gram” is in full swing. The Japan­ese phar­ma is set to let go a to­tal of 641 work­ers in Mass­a­chu­setts: 495 in

Zealand Phar­ma ap­pears to have tak­en a small step for­ward with a can­di­date that tar­gets both GLP-1 and GLP-2, an ap­proach that aims to ease

Less than a month af­ter re­veal­ing pipeline cuts amid dis­ap­point­ing gene ther­a­py sales, Bio­Marin is now down­siz­ing its team. The biotech said it will lay

Pathios Ther­a­peu­tics drew in $25 mil­lion for the first close of a Se­ries B raise that should help the UK biotech test its first-in-class sol­id